Menotrophin Ferring-Léciva

Menotrophin, the active ingredient in Menotrophin Ferring‑Léciva, is a gonadotropin (FSH/LH mixture) presented as a sterile injectable solution for subcutaneous use. It is employed to treat infertility caused by anovulation and to support assisted reproductive technologies in women, including in vitro fertilisation cycles, by promoting follicular growth and ovulation.

GNH USA supplies Menotrophin Ferring‑Léciva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality assurance, regulatory compliance and reliable cold‑chain logistics for this biologic product.

Menotrophin is used in reproductive endocrinology to stimulate ovarian follicular development and ovulation. - Infertility due to anovulation: stimulates follicular growth and induces ovulation in women who do not ovulate spontaneously. - Controlled ovarian stimulation for assisted reproductive technologies (e.g., IVF): supports development of multiple follicles to increase the number of retrievable oocytes. - Induction of ovulation in women with hypogonadotropic hypogonadism: provides necessary FSH and LH activity to trigger ovulation in patients with deficient gonadotropin secretion.

Menotrophin may be associated with several adverse reactions, ranging from mild to severe.

Common Side Effects: - Injection site pain - Mild abdominal bloating - Nausea - Headache

Serious or Rare Side Effects: - Ovarian hyperstimulation syndrome - Multiple pregnancy - Allergic reaction or anaphylaxis - Thromboembolic events

When using Menotrophin, clinicians should observe specific precautions to minimise risks and ensure optimal outcomes. - Monitor ovarian response: perform ultrasound and estradiol assessments to adjust dose. - Avoid use in pregnancy: the drug is contraindicated once pregnancy is confirmed. - Assess for hypersensitivity: discontinue if signs of allergic reaction appear. - Use caution in patients with ovarian cysts: may exacerbate cyst growth. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Menotrophin can interact with other medicines that affect hormonal balance or coagulation.

Major Interactions (Avoid): - Gonadotropin‑releasing hormone agonists or antagonists: may blunt the intended ovarian response. - Aromatase inhibitors: can reduce estrogen synthesis and diminish efficacy. - Anticoagulants: increased risk of thrombosis if ovarian hyperstimulation occurs.

Moderate Interactions (Monitor Closely): - Oral contraceptives: suppress endogenous gonadotropins and may require washout before treatment. - Thyroid hormone therapy: altered metabolism may affect drug activity. - Steroid medications: can influence ovarian response and require dose adjustment.